Is GHK-Cu legal in the US?

By The Docket DeskResearched & sourcedUpdated 13 Sep 2026

The short answer

GHK-Cu is not an FDA-approved drug in any form — but unlike the other peptides we track, its compounding status splits by route. Non-injectable GHK-Cu is listed in the FDA’s 503A Category 1, which means the agency does not intend to act against a pharmacy that compounds it under the stated conditions. Injectable GHK-Cu is on no category list at all. The FDA has said it will consult its advisory committee on GHK-Cu before the end of February 2027.

FDA approvalNot approved

Compounding · non-injectable503A Category 1 — within FDA’s interim enforcement policy (not an approval)

Compounding · injectableOn no category list since April 2026 — not authorized

Under FDA reviewPCAC · before end of Feb 2027

Use under reviewNot stated — FDA’s notice names no indication

Earliest pharmacy accessNon-injectable: available now under the interim policy · injectable: late 2027 at the earliest, if cleared

Approved vs compoundable vs “research-use” — the distinction that matters

An FDA-approved drug has cleared full clinical trials. A compoundable substance is one a licensed pharmacy may prepare to prescription, even without full approval, if it sits on the 503A Category 1 list. GHK-Cu is the one substance we track where this turns on the route of administration. On 22 April 2026 the FDA removed GHK-Cu from Category 1 because its nominations had been withdrawn. On 5 May one of the nominators clarified that it had meant to withdraw only the injectable route and wished to keep the nomination for non-injectable use, so the entry “GHK-Cu (except for injectable routes of administration)” was added back to Category 1. That is where it stands: non-injectable inside the interim policy, injectable outside every list. Category 1 is not approval — it is a statement that the FDA does not intend to take action while it finishes evaluating the substance. Products labeled “for research use only” are not authorized for human use. This page does not provide sourcing, dosing, or preparation guidance.

What happens before the end of February 2027

The FDA has announced that it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether GHK-Cu should go on the 503A bulks list. The notice does not name an indication, and it does not separate the routes. A favorable vote would be a recommendation only; the FDA would still have to complete rulemaking, which on this list has taken years rather than months. For the injectable route, realistic access is late 2027 at the earliest. For non-injectable use nothing needs to change: it is already inside the interim policy.

Will GHK-Cu become legal in 2026?+

The question has two answers. Non-injectable GHK-Cu already sits in 503A Category 1 and may be compounded under the FDA’s interim policy. Injectable GHK-Cu is on no list, and nothing changes for it before the advisory committee meets, due before the end of February 2027. Even a favorable vote there is a recommendation, not a rule.

Is “research-grade” GHK-Cu the same as a medicine?+

No. Material sold “for research use only” is not made or tested to pharmaceutical standards, is not authorized for human use, and carries no guarantee of identity, purity or sterility. This site does not link to or evaluate these sellers.

Primary sources: FDA, “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A”, updated 14 May 2026 (the Category 1 entry, the 22 April removal, the 5 May clarification and the February 2027 PCAC announcement) · FDA interim policy on compounding with bulk drug substances · FDA Advisory Committee Calendar.

Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. GHK-Cu is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.